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Healthcare–associated pneumonia (HCAP) is a newly identified condition and epidemiologic 
studies in Japan are still limited. We retrospectively observed patients with HCAP and 
community-acquired pneumonia (CAP) who were hospitalized between December 2004 and 
March 2005, and compared their disease characteristics. A total of 34 patients (14 with 
HCAP and 20 with CAP) were evaluated. Of the patients with HCAP, seven (50%) were 
hospitalized for at least 2 days in the preceding 90 days and five (35.7%) resided in a nursing 
home or extended care facility. Compared with patients with CAP, patients with HCAP were 
older, had more complications, including central nerve diseases, had greater disease severity, 
but lower serum albumin level. More methicillin-resistant Staphylococcus aureus, 
Pseudomonas spp. and anaerobes were isolated from patients with HCAP than from those 
with CAP. Conversely, more Streptococcus pneumoniae was detected and more penicillin 
was used in patients with CAP. This study provides additional evidence that HCAP should be 
distinguished from CAP and suggests the pathogenesis and therapeutic strategy for HCAP 
may be similar to those of hospital-acquired pneumonia (HAP). 
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Healthcare–associated pneumonia (HCAP) is a newly identified condition and has 
been documented in the 2005 American Thoracic Society (ATS)/Infectious Diseases Society 
of America (IDSA) guidelines [1]. Previously, the cases of HCAP substantially overlapped 
with those of community-acquired pneumonia (CAP); however, HCAP is distinct from CAP 
because the epidemiologic pattern of HCAP is similar to that of hospital–acquired pneumonia 
(HAP), which has risk factors for multidrug-resistant (MDR) pathogens [2-3]. 
 Kollef et al. analyzed 4,543 patients with culture-positive pneumonia admitted into 59 
US hospitals and found that approximately one-half of hospitalized patients with pneumonia 
had CAP and >20% had HCAP. They reported that the mortality rates associated with HCAP 
(19.8%) and HAP (18.8%) were comparable (p > 0.05) and both were significantly higher 
than that for CAP (10%, all p < 0.0001) and lower than that for ventilator–associated 
pneumonia (29.3%, all p < 0.0001) [4]. 
 Micek et al. also analyzed 639 patients in the United States and reported that HCAP 
was more common than CAP (67.4% versus 32.6%) and that the hospital mortality rate was 
statistically greater among patients with HCAP than with CAP (24.6% versus 9.1%; P < 
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0.001) [5]. These studies recommended early and appropriate administration of antibiotics 
similar to the strategy for patients with HAP.  
In contrast, the British Thoracic Society guidelines have documented that patients 
with nursing home–acquired pneumonia (NHAP), which is usually categorized with HCAP, 
should be treated as having CAP because there is no difference in the distribution of 
causative pathogens between patients with NHAP and other older adults with CAP[6-7]; this 
is similar to other recent studies regarding NHAP and pneumonia in residents of long-term 
care facilities [8-9]. These studies suggested that the pathogenesis of HCAP is heterogeneous 
and further evidence is required to clarify the differences among HCAP, CAP, and HAP.  
The objective of this study was to determine the differences in baseline characteristics 
between patients with HCAP and CAP in Japan and to clarify the strategy for the treatment of 
HCAP. In particular, we focused on patient background, disease severity, and specific 
characteristics, including physical examination and laboratory data, of patients with HCAP.  
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MATERIALS and METHODS 
 
Study design and patient population 
We conducted a retrospective observational study of patients with pneumonia 
hospitalized at Kitakyusyu City Yahata Hospital (a 300-bed community hospital in 
Kitakyusyu City, Fukuoka, Japan) between December 1, 2004 and March 30, 2005. Patients 
with HAP were excluded. We categorized the study patients into HCAP or CAP groups and 
compared baseline characteristics, disease severity, pathogen distribution, antibiotic regimens, 
and clinical outcomes between the pneumonia groups. We adhered to the Japanese ethical 
guidelines for epidemiologic studies and the protocol of this study was approved by the ethics 
committees of Kitakyushu City Yahata Hospital and Nagasaki University.  
 
Definitions 
HCAP and CAP were defined according to the ATS/IDSA guidelines [1-3]. HCAP 
was determined in patients with any of the following: (1) hospitalization for ≥2 days in the 
preceding 90 days; (2) residence in a nursing home or extended care facility; (3) home 
infusion therapy (including antibiotics); (4) long-term dialysis (including hemodialysis and 
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peritoneal dialysis) within 30 days of entering the study; or (5) home wound care. 




Pathogens in samples obtained from respiratory tracts, blood, and other samples were 
investigated. These samples were cultured in sheep blood agar, chocolate agar, and potato 
dextrose agar in a semiquantitative manner. Positive bacterial culture results for respiratory 
tracts, other than for the normal flora, are described in the table of microbial identification. 
Serologic methods using single or paired sera were used to detect antibodies against 
Mycoplasma pneumoniae and Chlamydophila pneumoniae. Influenza virus antigen in 
nasopharyngeal swabs and Legionella pneumophila serogroup 1 antigen in urine samples 
were detected by immunochromatography.  
 
Disease severity evaluation 
Pneumonia severity was assessed by a clinical severity scale, the Pneumonia Severity 
Index (PSI), published by IDSA, which was calculated from data regarding age, 
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complications, physical examination findings, and laboratory data on admission [2, 13]. 
Chest X-ray findings were reviewed and assessed by three physicians blindly and the levels 
of infiltrates were determined. 
The severity of pneumonia was also evaluated using the predictive rules for CAP and 
HAP in Japan proposed by the Japanese Respiratory Society: the A-DROP (age, dehydration, 
respiratory failure, orientation disturbance, and low blood pressure)[14] and the I-ROAD 
(immunodeficiency, age, respiratory failure, orientation disturbance, and dehydration)[11, 15] 
5-point scoring system, respectively. Those are modified versions of the CURB-65 
(confusion, blood urea nitrogen >20 mg/dL, respiratory rate >30 breaths/min, systolic blood 
pressure <90 mmHg or diastolic blood pressure <60 mmHg, and age >65 years) clinical 
prediction rule[2, 6]. 
 
Statistical analysis 
A statistical software package (SPSS for Windows, version 16.0J; SPSS Inc., Chicago, 
IL) was used for all statistical comparisons. Comparisons between groups were carried out 
using the most appropriate test from the chi-square test, the Wilcoxon test for continuous 
variables, Fisher’s-exact test, and student’s paired t-test. Additionally, relative coefficients by 
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Pearson’s and Spearman’s rank correlation tests were calculated for the mortality rate. P 
values of <0.05 were considered statistically significant.





A total of 34 patients were evaluated during the study period, comprising 14 patients 
with HCAP (41.2%) and 20 patients with CAP (58.8%). Of the patients with HCAP, seven 
(50%) had been hospitalized for at least 2 days in the preceding 90 days and five (35.7%) 
resided in a nursing home or extended care facility. Two (14.7%) were receiving home 
infusion therapy (including antibiotics). There were no patients who had a background of 
long-term dialysis within 30 days and home wound care (data not shown). 
Patients with HCAP were significantly older than those with CAP, but the 
male/female ratio did not differ substantially between the two groups (Table 1). In addition, 
all 14 of the patients with HCAP (100%) had complications, in contrast to only 14 (75%) of 
the patients with CAP. Among complications, central nerve diseases were significantly found 
in patients with HCAP compared to those with CAP. The incidences of chronic lung diseases, 
including old tuberculosis, bronchial asthma, COPD, and idiopathic pulmonary fibrosis, 
chronic heart diseases, neoplastic diseases, collagen diseases, liver disease, and diabetes were 
similar between the two groups. 
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Physical examinations and laboratory data 
Fever was the most common physical finding, but the average temperature was not 
higher in patients with HCAP than in those with CAP (Table 2). Heart rate, respiratory rate, 
and the number of dehydrated and disoriented patients were the same between the two groups. 
The laboratory findings, including white blood cell count and C-reactive protein level, 
were nearly similar between the two groups. The saturation of peripheral oxygen (SpO2) level 
was not different between the two groups. However, serum albumin levels were significantly 
lower in patients with HCAP compared to those with CAP. 
Chest infiltrates comprised the most common radiographic abnormality in patients 
with HCAP. The percentage of patients who had severe levels of infiltrates, occupying over 
two-thirds of the lateral lung field, was significantly higher in patients with HCAP (21.4%) 
than in patients with CAP (5.0%). In contrast, the percentage of patients who had mild levels, 
less than one-third of the lateral lung field occupied by infiltrates, was significant lower in 
patients with HCAP (42.6%), compared to patients with CAP (85.0%). 
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Disease severity 
The severity of HCAP was assessed by the criteria of the PSI of IDSA, A-DROP, and 
I-ROAD of the Japanese Respiratory Society, respectively (Table 2). The PSI of patients with 
HCAP was significantly higher than that of patients with CAP. However, the A-DROP score 
of patients with HCAP was relatively similar to that of patients with CAP. In contrast, the I-
ROAD score of patients with HCAP was significantly higher than that of patients with CAP. 
 
Pathogen distribution 
The microbes identified in the HCAP and CAP groups are shown in Table 3. MRSA 
and anaerobes were detected more frequently in patients with HCAP than in patients with 
CAP. Conversely, Streptococcus pneumoniae was more frequently isolated from patients 
with CAP. In addition, the isolation rates of Gram-negative pathogens were the same between 
the two groups; however, Pseudomonas species, which have potential antibiotic resistance, 
were isolated significantly from patients with HCAP, but not from those with CAP. 
 
Antibiotic treatment and clinical outcomes 
Table 4 shows the initial antibiotic treatments of patients with HCAP and CAP. 
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Patients with HCAP generally received antibiotic monotherapy, especially with carbapenems 
and quinolones as the initial treatment. Among the antibiotics, penicillin was used statistical 
less frequently in patients with HCAP compared to those with CAP.  
Combination therapy was also generally used in patients with HCAP. Anti-MRSA 
drugs, quinolones, carbapems, and aminoglycosides were used as combined antibiotics. 




This retrospective study showed differences in baseline characteristics, disease 
severity, identified pathogens, initial antibiotic regimens, and clinical outcomes between 
patients with HCAP and those with CAP.  
Among the 14 patients with HCAP, seven (50%) had been hospitalized for at least 2 
days in the preceding 90 days and five (35.7%) resided in a nursing home or extended care 
facility. Shindo et al. reported that 39% of patients with HCAP had been hospitalized for at 
least 2 days in the preceding 90 days and 61.0% resided in a nursing home or extended care 
facility [12]. Maruyama et al. reported that in a rural region of Japan where the population 
over 65 years of age represents 30% of the population, 69.4% were patients with HCAP 
(NHAP) and 30.6% were patients with HAP [16]. Although the proportion of patients with 
NHAP in our studies was relatively low, it may be due to differences in the character of each 
hospital and local environment.  
We found that patients with HCAP were older than those with CAP, results that 
support two studies from Japan [12, 16]. Complications were also more frequently found in 
patients with HCAP. Among these complications, central nerve diseases were more prevalent 
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in patients with HCAP, while chronic lung diseases and heart disease were more prevalent in 
patients with CAP. These characteristics were similar to the reports of Murayama et al. [16], 
but much different from the results in the United States [4-5] suggesting a high frequency of 
aspiration pneumonia in elderly patients with old brain infarction in Japan. 
Physical examinations and laboratory findings of patients with HCAP were similar to 
those of patients with CAP, but patients with HCAP were older and had significantly lower 
serum albumin level compared to those with CAP. In addition, greater disease severity was 
found in patients with HCAP compared to those with CAP. We did not find significant 
different mortality between HCAP and CAP in this study (21.4% vs. 10.0%, respectively: 
p=0.3544, data not shown), however, lower serum albumin was related with mortality in 
patients with HCAP (P<0.0308, data not shown). Malnutrition may be one of the most 
important factors that affects prognosis apart from being a risk factor for pneumonia[17-18].  
It strongly suggested that a lower serum albumin level is related with elderly age and 
lower performance status of patients with NHAP [16], and  in other study of NHAP, poor 
functional status has been also correlated with the presence of MDR pathogens [18]. We did 
not investigate patients’ performance status in this study; however, performance status may 
be a potential prognosis factor for patients with HCAP. Further investigation is needed. 
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We isolated more MRSA, Pseudomonas spp. and anaerobes in patients with HCAP; 
however, S. pneumonia was more frequently isolated and penicillin was more frequently 
administered in patients with CAP in this study. Furthermore, the larger number of anaerobes 
suggested a higher incidence of aspiration pneumonia in patients with HCAP in Japan and 
was related with older age, central nerve diseases rates, and hypoalbuminemia in these 
patients.  
We previously reported that HAP in Japan included a large number of mild to 
moderate cases of aspiration pneumonia and these patients received excessive antibiotic 
therapy, although most cases of HAP in the United States were moderate to severe ventilator-
associated pneumonia and physicians responded with strong antibiotic therapy, e.g. de-
escalation therapy [11, 15]. In Japan, hospitals serve not only as acute care facilities, but also 
as nursing homes. Patients who have chronic diseases in Japan usually stay much longer in 
hospitals than those in the United States. This is one of the most important reasons for the 
high incidence of aspiration pneumonia in cases of HAP in Japan.  
Moreover, these patients were usually delivered to emergency hospitals and counted 
and treated as having CAP. Previously, a substantial number of patients with HCAP were 
counted and treated as having CAP [3-4].  
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The results of this study justify the separation of a new type of pneumonia, HCAP, 
from the traditionally defined CAP domain. HCAP is distinct from CAP in terms of patient 
characteristics, pathogen distribution patterns, and clinical outcomes. HCAP is also different 
from HAP and ventilator–associated pneumonia along the above-mentioned dimensions; 
however, in general, HCAP differs from HAP and ventilator–associated pneumonia to a 
lesser degree than from CAP. Given that the data in this study were derived from a 
consortium of hospitals typical of acute care hospitals in Japan, it is reasonable to expect that 
at the present time, a large proportion of patients hospitalized in acute-care facilities are being 
treated for CAP but in fact should be treated for HCAP, resulting in potentially poor clinical 
outcomes.  
Craven and Zilberberg et al. emphasized that the early initiation of appropriate and 
adequate antibiotic therapy was important for improving the outcomes of patients with HCAP 
[19-20].  In this study, the data suggest that patients with HCAP tended to have risk factors 
for MRSA, which should be treated with vancomycin or linezolid, as recommended by the 
2005 ATS/IDSA-HAP guidelines [1], even if the patients are not classified as having a severe 
disease. Therefore, HCAP should be identified as a distinct entity in determining the initial 
empirical antibiotic treatment, as stated in recent reports [3].  
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In conclusion, we found that patients with HCAP were significantly older and had 
more central nerve diseases than those with CAP. MRSA and anaerobes were more 
frequently identified from patients with HCAP than from patients with CAP. These results 
provide additional evidence that HCAP should be distinguished from CAP. Moreover, we 
showed that the occurrence of malnutrition, including hypoalbuminemia might have the 
potential to be a prognosis factor. Diagnostic and therapeutic strategies for HCAP may be the 
key to improving mortality in patients with HCAP and physicians need to consider MRSA 
and anaerobic pathogens in choosing the initial empirical antibiotic treatment of HCAP.
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TABLES 
Table 1. Subject demographics patients with healthcare-acquired pneumonia and those with 
community-acquired pneumonia 
 
CAP (n = 20)   HCAP (n = 14)  p-value 
Age (years)      53.819.5   77.29.7   0.0001*** 3) 
Sex (male/female)    12/8    8/6    0.8002 1) 
Complications    15 (75.0%)   14 (100.0%)   0.0428* 1) 
 Chronic lung diseases  10/20 (50.0%)   7/14 (50.0%)  1.0000 2) 
 Chronic heart diseases  2/20 (10.0%)   1/14 (7.1%)   0.6350 2) 
 Neoplastic diseases   0/20 (0.0%)   2/14 (14.3%)   0.0815 1) 
 Central nerve diseases  0/20 (0.0%)   4/15 (28.6%)   0.0216* 2) 
 Liver diseases   2/20 (10.0%)   1/14 (7.1%)   0.6350 2) 
 Collagen diseases   1/20 (5.0%)   1/14 ( 7.1%)   0.6613 2) 
 Diabetes mellitus   4/20 (20.0%)   1/14 (7.1%)   0.2975 1) 
 
Age is expressed as means SD. #Includes overlapping cases. CAP, community-acquired 
pneumonia; HCAP, healthcare–associated pneumonia  
1)2-test, 2)Fisher’s exact-test, 3)t-test; *p<0.05, **p<0.01, ***p<0.001.  
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CAP (n = 20)   HCAP (n = 14)  p-value 
Body Temperature, C   37.01.0  37.71.4  0.7392 2) 
Heart rate, /min   90.719.2  83.314.5  0.2317 2) 
Respiratory rate, /min   22.15.8   26.98.4   0.0588  3) 
Dehydration     16 (80.0%)  12 (85.7%)  0.6678 1) 
Disorientation    6 (30%)  7 (50%)  0.2376 1) 
WBC, /mm3     11125.69514.3  10072.13687.3 0.5386 3) 
Albumin, mg/dl    3.700.42  3.06 0.64      0.0050** 3) 
CRP, mg/dl     6.43.0  8.22.3  0.4785 3) 
SpO2, %     93. 5 0.8   91.07.3   0.2452 3) 
Chest Infiltrates#:              0.0452*1) 
 >2/3    1 (5.0%)  3 (21.4%) 
 Middle    2 (10.0%)   5 (35.7%) 
  <1/3    17 (85.0%)   6 (42.6%) 
PSI     59.322.7  91.516.9   0.0001*** 2) 
A-DROP            0.2820 1) 
 Severe    2 (10.0%)  8 (57.1%) 
 Moderate   12 (60.0%)    6 (42.9%) 
 Mild    6 (30.0%)   0 (0.0%) 
I-ROAD          0.0162*  3) 
 Severe    9 (45.0%)   12 (85.7%) 
 Moderate   0 (0.0%)     0 (0.0%) 
 Mild    11 (55.0%)   2 (14.3%) 
Body temperature, blood pressure, respiratory rates, and white blood cell count (WBC)  are 
expressed as meansSD. CAP, community-acquired pneumonia; HCAP, healthcare–
associated pneumonia; C-reactive protein; SpO2, saturation of peripheral oxygen. 
#Includes 
overlapping cases  1)2-test, 2)Wilcoxon’s rank test, 3)t-test; *p<0.05, **p<0.01.  
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Table 3 Microbes identified in patients with healthcare-acquired pneumonia and those with 
community-acquired pneumonia# 
 
Microbes    CAP   HCAP    p-value  
                              Patients  Patients  
     (n = 20)   (n = 14)  
Gram-negative pathogens    5 (25.0)    4 (28.6)   0.5718  2) 
Klebsiella species    0 (0)     1 (7.1)   0.2251  1) 
ESBLs    0 (0)    0 (0)  
Pseudomonas species   0 (0)   3 (21.4)  0.0302* 1) 
Escherichia coli    0 (0)    0 (0)  
Haemophilus influenzae  2 (10.0)  0 (0)    0.1291  1) 
Moraxella catarhalis  3 (15.0)   0 (0)   0.0886 1)  
Other Gram-negative bacteria 0 (0)     0 (0)  
 
Gram-positive pathogens  14 (70.0)   8 (57.1)  0.3404   2) 
Streptococcus pneumoniae  13 (65.0)   3 (21.4)  0.0399*  2) 
MSSA     1 (5.0)     0 (0)   0.3958   1)  
MRSA     0 (0)     3 (21.4)  0.0302*  1) 
 
Atypical pathogens    1 (5.0)    0 (0)   0.3958   1) 
Chlamydophila pneumoniae  0 (0)     0 (0)  
Mycoplasma pneumoniae    0 (0)     0 (0)  
Legionella pneumophila    0 (0)    0 (0)  
Influenza virus           2 (10.0)            3 (21.4)   0.1621   1) 
 
Anaerobes       0 (0)    3 (21.4)   0.0302* 1) 
#Includes overlapping cases 
CAP, community-acquired pneumonia; HCAP, healthcare–associated pneumonia; ESPLs, 
extended-spectrum -lactamase producing bacteria; MSSA, methicillin-sensitive 
Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.  
1)2-test; 2)Fisher’s exact-test; *p<0.05.  
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Table 4. Antibiotic treatment of patients with healthcare-acquired pneumonia and those with 
community-acquired pneumonia #  
 
Therapy and outcomes   CAP  HCAP  p-value 
                              Patients  Patients     
(n = 20)  (n = 14) 
     
Monotherapy      18 (90.0)           11 (78.5)   0.6613 2) 
Penicillin    13 (65.0)  2 (14.2)  0.0145*  2) 
3rd or 4th Cefems   3 (15.0)  3 (21.6) 0.2486 1) 
Carbapenems    2 (10.0) 3 (21.6) 0.1621 1) 
Quinolones    0 (0)   1 (7.1)  0.2251 1) 
Anti-MRSA   0 (0)   2 (14.2)  0.1291 1) 
  
Combination therapy    2 (10.0) 3 (21.6) 0.1621 1) 
Carbapenems + Anti-MRSA  0 (0)   1 (7.1)  0.2251 1) 
Carbapenems + Quinolones  0 (0)   1 (7.1)  0.2251 1) 
Clindamycin + 3rd Cefems  1 (5.0)    0 (0)  0.3958 1) 
Clindamycin + Quinolones  1 (5.0)    0 (0)  0.3958 2) 
Aminoglycoside + Anti-MRSA  0 (0)   1 (7.1)  0.2251 1) 
 
#Includes overlapping cases 
CAP, community-acquired pneumonia; HCAP, healthcare–associated pneumonia; anti-
MRSA, anti-methicillin-resistant Staphylococcus aureus.  
1)2-test; 2)Fisher’s exact-test; *p<0.05  
 
